The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...
Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some ...
While attention has been on Apple’s progress (or lack thereof) in Research Triangle Park, the company continues to spend on a data center 150 miles away in the Catawba County town of Maiden.
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...
Champaign, Ill.-based Health Alliance and Southern Pines, N.C.-based FirstCarolinaCare will no longer offer any insurance plans past 2025, with the exception of Medicare Advantage. The organizations ...
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...
AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...
The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...